Literature DB >> 11710681

Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically.

J L Frater1, K F McCarron, J P Hammel, J L Shapiro, M L Miller, R R Tubbs, J Pettay, E D Hsi.   

Abstract

We compared the features of 17 cases of atypical chronic lymphocytic leukemia (aCLL) with those of a clinical control group of 24 cases of CLL. Quantitative flow cytometric data, available for 12 cases, were compared with an immunophenotypic control group of 58 cases using a relative fluorescence indexfor CD5, CD23, CD79b, and surface immunoglobulin light chain (sIg). Compared with the clinical control group, patients with aCLL had a higher mean WBC count and a lower platelet count. Patients with aCLL had a significantly higher probability of disease progression. Compared with an immunophenotypic control group of 58 CLL cases, 12 cases of aCLL demonstrated significantly higher expression of CD23. There was no significant difference in expression of sIg, CD79b, or CD5 between the groups. CD38 expression was noted in only 1 (9%) of 11 tested cases; 2 (18%) of 11 cases had trisomy 12. aCLL can be distinguished from typical CLL morphologically, clinically, and immunophenotypically. Atypical morphologic features in CLL seem to be a marker of aggressive clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710681     DOI: 10.1309/7Q1J-1AA8-DU4Q-PVLQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior.

Authors:  Mi-Ae Jang; Eun-Hyung Yoo; Kihyun Kim; Won Seog Kim; Chul Won Jung; Sun-Hee Kim; Hee-Jin Kim
Journal:  Int J Hematol       Date:  2013-02-12       Impact factor: 2.490

2.  CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Authors:  Roxana S Dronca; Dragan Jevremovic; Curtis A Hanson; Kari G Rabe; Tait D Shanafelt; William G Morice; Timothy G Call; Neil E Kay; Charles S Collins; Susan M Schwager; Susan L Slager; Clive S Zent
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

3.  Concomitant Diagnosis of Primary Bone Marrow B-Cell Non-Hodgkin Lymphoma and Essential Thrombocythemia: A Case Report.

Authors:  Hongkyung Kim; Hye Min Kim; Jin Ju Kim; Saeam Shin; Doh Yu Hwang; Seung-Tae Lee; Jong Rak Choi
Journal:  Ann Lab Med       Date:  2022-03-01       Impact factor: 3.464

4.  Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Authors:  Shuhua Yi; Zengjun Li; Dehui Zou; Wenjie Xiong; Heng Li; Rui Cui; Chengwen Li; Yuting Yan; Wei Liu; Rui Lv; Zhen Yu; Weiwei Chen; Yan Xu; Gang An; Huijun Wang; Kun Ru; Tao Cheng; Jianxiang Wang; Lugui Qiu
Journal:  Oncotarget       Date:  2017-12-15

5.  Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis.

Authors:  Ramya Muddasani; Neel Talwar; Jaime Andres Suarez-Londono; Marc Braunstein
Journal:  Clin Case Rep       Date:  2020-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.